ArticlePediatric research2026
Claudin-3 as a marker of intestinal permeability and its relation to inflammatory status in adolescents with functional gastrointestinal disorders.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFunctional Gastrointestinal disorders (FGIDs) are highly prevalent among adolescents. Increased intestinal permeability plays a potential role in the pathogenesis of FGIDs. Claudin-3 (CLDN3) may serve as an indicator of gut barrier integrity. We aimed to assess serum level of CLDN3 as a noninvasive biomarker of intestinal permeability in adolescents with FGIDs, and its relation with inflammatory markers.
methodsThis study included 70 adolescents with FGIDs and 65 healthy controls. Serum levels of CLDN3 and inflammatory markers; C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor alpha (TNFα), and haptoglobin, were measured using enzyme-linked immunosorbent assay.
resultsSerum levels of CLDN3 and inflammatory markers; CRP, Il-6, TNFα and haptoglobin, were significantly higher in cases compared to controls (p = 0.02, 0.039, 0.04, 0.021 and 0.001, respectively). We detected significant positive correlations between serum level of CLDN3 and that of CRP, IL-6 and haptoglobin in cases.
conclusionOur results revealed significant elevations in serum levels of CLDN3 and inflammatory markers in adolescents with FGIDs. Significant positive correlations were detected between levels of CLDN3 and that of CRP, IL-6 and haptoglobin, suggesting an association between intestinal barrier dysfunction and low-grade systemic inflammation. Thus, CLDN3 represents a potential noninvasive biomarker of intestinal permeability in FGIDs. IMPACT: This research investigated the potential role of Claudin-3 (CLDN3) as a noninvasive biomarker of intestinal permeability in adolescents with Functional Gastrointestinal Disorders (FGIDs), and its relation to the inflammatory status of these patients. To the best of our knowledge, this is the first study to assess serum CLDN3 as a noninvasive biomarker of intestinal permeability in FGIDs; previous researches have assessed intestinal barrier disruption in FGIDs based on intestinal biopsies. Our findings suggest that impaired intestinal barrier function may promote development of FGIDs by inducing inflammation. Thus, restoration of intestinal barrier integrity may represent a potential therapeutic target for FGIDs.
Identifiers
42834155What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.